@article{atak_acute_2021,
	title = {Acute generalized exanthematous pustulosis following treatment with favipiravir in a patient with {COVID}-19 without hydroxychloroquine use: {Report} of the first case},
	volume = {20},
	copyright = {All rights reserved},
	issn = {1473-2165},
	shorttitle = {Acute generalized exanthematous pustulosis following treatment with favipiravir in a patient with {COVID}-19 without hydroxychloroquine use},
	url = {http://www.ncbi.nlm.nih.gov/pubmed/34139069},
	doi = {10.1111/jocd.14304},
	language = {eng},
	number = {8},
	journal = {Journal of Cosmetic Dermatology},
	author = {Atak, Mehmet Fatih and Farabi, Banu and Akbayrak, Atiye and Kalelioğlu, Mehmet Berati and Rao, Babar K.},
	month = aug,
	year = {2021},
	keywords = {AGEP, Amides, COVID-19, COVID-19 Drug Treatment, Humans, Hydroxychloroquine, Pyrazines, SARS-CoV-2, acute generalized exanthematous pustulosis, cutaneous adverse event, favipiravir},
	pages = {2387--2389},
}

{"_id":"SJ47BiAAWJRWd24RY","bibbaseid":"atak-farabi-akbayrak-kaleliolu-rao-acutegeneralizedexanthematouspustulosisfollowingtreatmentwithfavipiravirinapatientwithcovid19withouthydroxychloroquineusereportofthefirstcase-2021","author_short":["Atak, M. F.","Farabi, B.","Akbayrak, A.","Kalelioğlu, M. B.","Rao, B. K."],"bibdata":{"bibtype":"article","type":"article","title":"Acute generalized exanthematous pustulosis following treatment with favipiravir in a patient with COVID-19 without hydroxychloroquine use: Report of the first case","volume":"20","copyright":"All rights reserved","issn":"1473-2165","shorttitle":"Acute generalized exanthematous pustulosis following treatment with favipiravir in a patient with COVID-19 without hydroxychloroquine use","url":"http://www.ncbi.nlm.nih.gov/pubmed/34139069","doi":"10.1111/jocd.14304","language":"eng","number":"8","journal":"Journal of Cosmetic Dermatology","author":[{"propositions":[],"lastnames":["Atak"],"firstnames":["Mehmet","Fatih"],"suffixes":[]},{"propositions":[],"lastnames":["Farabi"],"firstnames":["Banu"],"suffixes":[]},{"propositions":[],"lastnames":["Akbayrak"],"firstnames":["Atiye"],"suffixes":[]},{"propositions":[],"lastnames":["Kalelioğlu"],"firstnames":["Mehmet","Berati"],"suffixes":[]},{"propositions":[],"lastnames":["Rao"],"firstnames":["Babar","K."],"suffixes":[]}],"month":"August","year":"2021","keywords":"AGEP, Amides, COVID-19, COVID-19 Drug Treatment, Humans, Hydroxychloroquine, Pyrazines, SARS-CoV-2, acute generalized exanthematous pustulosis, cutaneous adverse event, favipiravir","pages":"2387–2389","bibtex":"@article{atak_acute_2021,\n\ttitle = {Acute generalized exanthematous pustulosis following treatment with favipiravir in a patient with {COVID}-19 without hydroxychloroquine use: {Report} of the first case},\n\tvolume = {20},\n\tcopyright = {All rights reserved},\n\tissn = {1473-2165},\n\tshorttitle = {Acute generalized exanthematous pustulosis following treatment with favipiravir in a patient with {COVID}-19 without hydroxychloroquine use},\n\turl = {http://www.ncbi.nlm.nih.gov/pubmed/34139069},\n\tdoi = {10.1111/jocd.14304},\n\tlanguage = {eng},\n\tnumber = {8},\n\tjournal = {Journal of Cosmetic Dermatology},\n\tauthor = {Atak, Mehmet Fatih and Farabi, Banu and Akbayrak, Atiye and Kalelioğlu, Mehmet Berati and Rao, Babar K.},\n\tmonth = aug,\n\tyear = {2021},\n\tkeywords = {AGEP, Amides, COVID-19, COVID-19 Drug Treatment, Humans, Hydroxychloroquine, Pyrazines, SARS-CoV-2, acute generalized exanthematous pustulosis, cutaneous adverse event, favipiravir},\n\tpages = {2387--2389},\n}\n\n\n\n","author_short":["Atak, M. F.","Farabi, B.","Akbayrak, A.","Kalelioğlu, M. B.","Rao, B. K."],"key":"atak_acute_2021","id":"atak_acute_2021","bibbaseid":"atak-farabi-akbayrak-kaleliolu-rao-acutegeneralizedexanthematouspustulosisfollowingtreatmentwithfavipiravirinapatientwithcovid19withouthydroxychloroquineusereportofthefirstcase-2021","role":"author","urls":{"Paper":"http://www.ncbi.nlm.nih.gov/pubmed/34139069"},"keyword":["AGEP","Amides","COVID-19","COVID-19 Drug Treatment","Humans","Hydroxychloroquine","Pyrazines","SARS-CoV-2","acute generalized exanthematous pustulosis","cutaneous adverse event","favipiravir"],"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/raoresearch","dataSources":["aGgndugSyribdb2rd","2tgmyzKov4y6MHvQs"],"keywords":["agep","amides","covid-19","covid-19 drug treatment","humans","hydroxychloroquine","pyrazines","sars-cov-2","acute generalized exanthematous pustulosis","cutaneous adverse event","favipiravir"],"search_terms":["acute","generalized","exanthematous","pustulosis","following","treatment","favipiravir","patient","covid","without","hydroxychloroquine","use","report","first","case","atak","farabi","akbayrak","kalelioğlu","rao"],"title":"Acute generalized exanthematous pustulosis following treatment with favipiravir in a patient with COVID-19 without hydroxychloroquine use: Report of the first case","year":2021}